Neoadjuvant BKM120 in High-risk Prostate Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

April 23, 2013

Primary Completion Date

February 5, 2015

Study Completion Date

February 5, 2015

Conditions
High Risk Prostate Cancer
Interventions
DRUG

BKM120

Two weeks after confirmatory biopsy, patients will begin taking 100 mg/day of BKM120. BKM120 will be given at this dose level orally once daily for 14 days prior to radical prostatectomy. Radical prostatectomy will be performed on the day of the last dose of BKM120 at day 14. No further drug will be administered after radical prostatectomy. For unforeseen delays in OR scheduling, up to 7 additional days of BKM120 may be administered prior to surgery.

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Won Kim

OTHER